Ikarovec key facts
- Operator of a gene therapy company intended to treat common eye diseases.
- Ikarovec’s last known valuation is $184.0M.
- It has raised $43.9M; the latest was Later Stage VC ($46.0M) in Oct 2025.
- Notable investors include Future Planet Capital, Parkwalk Advisors, Cambridge Enterprise Ventures, UK Innovation & Science Seed Fund, BioIndustry Association — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Ikarovec: the Monday email on marks, rounds and moves
Ikarovec funding rounds
No funding rounds for Ikarovec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ikarovec valuation
Ikarovec's last known valuation is $184 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Ikarovec investors
7 investors are on record for Ikarovec, including Future Planet Capital, Parkwalk Advisors, Cambridge Enterprise Ventures and UK Innovation & Science Seed Fund.
About Ikarovec
Operator of a gene therapy company intended to treat common eye diseases. The company targets multiple disease targets and pathways that help in targeting multiple disease targets and pathways treatment for diabetic macular edema, dry-form age-related macular degeneration, neovascular (wet-form) age-related macular degeneration, and ocular hypertension, enabling patients to get the required treatment for restoring sight and preventing blindness.
- Sector
- Healthcare
- HQ
- Norwich, United Kingdom
- Founded
- 2018
- Employees
- 8
- Website
- ikarovec.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Ikarovec’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.